New DNA-based antibodies to fight drug-resistant infections
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
This study is testing a new type of treatment using special antibodies that can be quickly made in your body to help fight tough infections caused by bacteria called Pseudomonas aeruginosa, which is especially for people who are at risk of serious infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10459450 on NIH RePORTER |
What this research studies
This research focuses on developing a novel type of monoclonal antibody, known as DNA-encoded monoclonal antibodies (DMAbs), to combat infections caused by multi-drug resistant Pseudomonas aeruginosa. The approach involves encoding the genes for these antibodies into DNA, which can be administered directly into the body, allowing for rapid production of the antibodies in response to infection. This method aims to overcome the limitations of traditional monoclonal antibody therapies, such as high costs and slow production times, making it a potentially more accessible treatment option for patients at risk of severe infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients at high risk for infections from multi-drug resistant Pseudomonas aeruginosa, particularly those undergoing medical procedures or with compromised immune systems.
Not a fit: Patients with infections caused by bacteria that are not Pseudomonas aeruginosa or those who do not have multi-drug resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, cost-effective treatment option for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in using monoclonal antibodies for infection control, but the specific approach of using DNA-encoded antibodies is relatively novel and untested.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Weiner, David B. — Wistar Institute
- Study coordinator: Weiner, David B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.